PETER P. PFREUNDSCHUH
CIK 1585839 · EVP, CFO and Treasurer · last filed 2025-09-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.02M
Companies
6
Total Filings
35
Lifetime Open-Market Net
-$317.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | CFO and Treasurer | 77,800 | $8.61 | $669.9K | $0 | 2 | 2025-01-22 |
| VYGR | Chief Financial Officer | 175,669 | $3.04 | $534.0K | -$122.9K | 6 | 2024-02-22 |
| Korro Bio, Inc. (FREQ) Delisted | Chief Financial Officer | 209 | $14.98 | $3.1K | -$27.6K | 6 | 2022-02-23 |
| URGN | Chief Financial Officer | 11,829 | $40.88 | $483.6K | -$166.7K | 11 | 2020-10-16 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | CFO | 0 | — | — | $0 | 3 | 2018-02-13 |
| IMMUNOMEDICS INC (IMMU) Delisted | Chief Financial Officer | 29,706 | — | — | $0 | 4 | 2015-08-24 |
Recent Filings · Page 3 of 4
35 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-20 | URGN | Mixed | +683 | -$9.0K | EDGAR |
| 2020-04-28 | URGN | Mixed | +276 | -$3.4K | EDGAR |
| 2020-02-24 | URGN | Mixed | +682 | -$10.7K | EDGAR |
| 2020-02-04 | URGN | Grant (A) | — | $0 | EDGAR |
| 2020-01-28 | URGN | Mixed | +999 | -$19.5K | EDGAR |
| 2019-11-22 | URGN | Mixed | +688 | -$10.1K | EDGAR |
| 2019-08-22 | URGN | Mixed | +2,751 | -$46.8K | EDGAR |
| 2019-01-29 | URGN | Grant (A) | — | $0 | EDGAR |
| 2018-02-13 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Disp (D) | −263 | -$4.7K | EDGAR |
| 2018-01-12 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +394 | $3.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.